Managing the behavioral changes that accompany cognitive decline is one of the most grueling aspects of caregiving for those with Alzheimer’s and other forms of dementia. Among these changes, agitation—characterized by restlessness, verbal aggression, or physical outbursts—often creates a crisis point for families and healthcare providers. For years, options for treating these symptoms were limited or carried significant risks.
Recent medical advancements have introduced a targeted pharmacological option to facilitate stabilize these symptoms. The FDA’s approval of brexpiprazole for the treatment of agitation associated with dementia marks a shift toward more evidence-based management of behavioral and psychological symptoms of dementia (BPSD). Although, medication is rarely the first line of defense. A comprehensive approach combining environmental modifications and precise medical intervention offers the best path forward for patient safety and quality of life.
Understanding Agitation in Dementia
Agitation isn’t a symptom of dementia itself, but rather a reaction to it. As the brain loses the ability to process information, patients often experience frustration, fear, or sensory overload. This can manifest as pacing, repetitive questioning, or sudden anger.
These episodes often stem from unmet needs that the patient can no longer communicate. For example, a patient might become agitated due to the fact that they are in pain, hungry, or confused by their surroundings. When these triggers aren’t identified, the agitation can escalate, leading to caregiver burnout and an increased risk of hospitalization.
The Role of Brexpiprazole in Treatment
Until recently, many physicians prescribed antipsychotics “off-label” to manage agitation. While effective, these drugs often caused heavy sedation or severe metabolic side effects. The introduction of brexpiprazole provides a more structured, approved alternative.
The FDA approved brexpiprazole for the treatment of agitation associated with dementia based on data from two randomized clinical trials. These studies demonstrated that the drug significantly improved agitation symptoms compared to a placebo. By modulating dopamine and serotonin receptors in the brain, brexpiprazole helps stabilize mood and reduce the intensity of behavioral outbursts without the extreme sedation associated with older antipsychotics.
“The approval of a medication specifically indicated for agitation in dementia provides clinicians with a tool that is backed by rigorous clinical trial data, rather than relying solely on off-label use.” Dr. Natalie Singh, Health Editor
Key Considerations for Medication
While the clinical trials showed promise, medication is a tool, not a cure. Patients and caregivers should be aware of the following:
- The Black Box Warning: All atypical antipsychotics, including brexpiprazole, carry a
black box warning
from the FDA. This indicates an increased risk of death and stroke in elderly patients with dementia-related psychosis. - Side Effect Profile: Common side effects may include somnolence (sleepiness), weight gain, or dizziness.
- Dosage Precision: Because the elderly metabolize medication differently, starting with the lowest effective dose is critical to avoid adverse reactions.
Beyond Medication: Non-Pharmacological Strategies
As a physician, I always emphasize that medication should be the last resort. The gold standard for dementia care is to first address the environment and the patient’s immediate needs.
Environmental Modifications
The physical space can either trigger or soothe a patient. Reducing “noise pollution”—such as loud televisions or crowded rooms—can significantly lower anxiety. Using soft lighting and maintaining a consistent daily routine provides the predictability that dementia patients crave.
Communication Techniques
When a patient becomes agitated, arguing or attempting to “correct” their reality often worsens the situation. Instead, caregivers should use validation therapy
, which involves acknowledging the patient’s feelings rather than the facts of their statement. If a patient is upset because they want to “go home” (even if they are already home), validating the feeling of longing is more effective than explaining that they are in their own living room.
Comparing Treatment Approaches
| Approach | Primary Goal | Best Used When… | Potential Risk |
|---|---|---|---|
| Non-Pharmacological | Reduce triggers and soothe anxiety | First-line intervention for all patients | Time-intensive for caregivers |
| Brexpiprazole | Stabilize mood and reduce agitation | Non-drug methods fail or patient is a danger to self/others | Increased risk of stroke or mortality in elderly |
| Off-Label Antipsychotics | Rapid sedation of acute outbursts | Emergency situations (rarely recommended long-term) | High risk of over-sedation and metabolic issues |
Key Takeaways for Caregivers
- Identify the trigger: Always check for pain, hunger, or environmental stress before assuming the agitation is purely biological.
- Start slow: If medication is necessary, ensure it is managed by a geriatric psychiatrist or neurologist who can monitor for the black box warning risks.
- Prioritize routine: A predictable schedule reduces the cognitive load on the patient, lowering the likelihood of outbursts.
- Validate, don’t correct: Focus on the emotion behind the agitation rather than the accuracy of the patient’s words.
Frequently Asked Questions
Can brexpiprazole cure Alzheimer’s disease?
No. Brexpiprazole does not treat the underlying cause of Alzheimer’s or slow the progression of cognitive decline. It is designed specifically to manage the behavioral symptom of agitation.
How long does it take for the medication to operate?
While some patients notice a difference quickly, the full therapeutic effect usually develops over several weeks. Consistent dosing and monitoring by a physician are required.
Should I stop the medication if the agitation goes away?
Never stop a psychiatric medication abruptly. Doing so can cause withdrawal symptoms or a rebound effect where agitation returns more severely. Always consult a doctor for a gradual tapering schedule.
Looking Ahead
The approval of targeted treatments like brexpiprazole represents a move toward personalized medicine in geriatric care. The future of dementia management lies in “precision behavioral health”—using a combination of genetic screening, environmental AI to detect triggers, and low-dose medications to maintain the patient’s dignity and safety. While we await a cure for the disease itself, improving the daily lived experience of patients and their families remains the most urgent priority.